Thomas John Charles, who serves as Executive Vice President and General Counsel at Krystal Biotech, Inc. (NASDAQ:KRYS), recently conducted a sale of company stock. On May 26, 2026, Mr. Thomas sold 642 shares of the corporation's common stock, with each share valued at $302.03. This transaction totaled $193,903.
The sale was executed utilizing a Rule 10b5-1 trading plan. Mr. Thomas originally adopted this specific trading arrangement on February 23, 2026. The terms of the plan dictate that it is scheduled to conclude either by December 31, 2026, or sooner if all shares of the company's common stock subject to the plan have been sold.
This recent transaction takes place amid notable market activity for Krystal Biotech. Shares are currently trading near their 52-week high of $319.48, and the stock has demonstrated a substantial return of 139% over the course of the past year. Furthermore, an analysis provided by InvestingPro suggests that the company may be undervalued at current valuation levels, noting the availability of 17 additional ProTips for subscribers interested in the biotech firm's investment potential.
Following the disposition of these shares, Mr. Thomas’s direct ownership stake in Krystal Biotech’s common stock has been reduced to zero shares.
Beyond this specific internal transaction, Krystal Biotech reported a highly successful start to 2026 when it released its first-quarter earnings. The company's financial performance exceeded market expectations across key metrics. Specifically, the firm achieved earnings per share (EPS) of $1.83. This figure represents a significant outperformance compared to the forecasted estimate of $1.48, marking an excess of 23.65%.
Revenue also showed robust growth, reaching $116.4 million. This total surpassed analyst predictions by 4.39%. The global Vyjuvek revenue for the first quarter amounted to this $116.4 million figure. Of this amount, $87 million was generated within the U.S., and $29 million originated from international markets. Both these divisional components exceeded the estimates set by BofA Securities and consensus market projections.
The company also achieved a major regulatory milestone: Krystal Biotech received marketing authorization from the United Kingdom’s Medicines and Healthcare products Regulatory Agency for its gene therapy, VYJUVEK. This approval is particularly noteworthy because it designates VYJUVEK as the initial genetic medicine in the UK specifically designed to treat dystrophic epidermolysis bullosa associated with COL7A1 gene mutations. These combined developments underscore Krystal Biotech’s recent operational achievements and strategic advancements.
Risks
- Reliance on Future Sales: The current valuation is supported by recent strong performance, but future stability depends on continued product success and market acceptance of VYJUVEK.
- Market Sensitivity to Changes: Although BofA Securities maintained a Buy rating, they concurrently lowered their price target from $325 to $323 due to an observed shift in the revenue mix, suggesting potential headwinds or shifts in investor perception.
More from Insider Trading
Risks
- Reliance on Future Sales: The current valuation is supported by recent strong performance, but future stability depends on continued product success and market acceptance of VYJUVEK.
- Market Sensitivity to Changes: Although BofA Securities maintained a Buy rating, they concurrently lowered their price target from $325 to $323 due to an observed shift in the revenue mix, suggesting potential headwinds or shifts in investor perception.